Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    June 2021
  1. SINGHAL SS, Srivastava S, Mirzapoiazova T, Horne D, et al
    Targeting the mercapturic acid pathway for the treatment of melanoma.
    Cancer Lett. 2021;518:10-22.
    PubMed     Abstract available

    April 2021
  2. COPPO R, Orso F, Virga F, Dalmasso A, et al
    ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.
    Cancer Lett. 2021;510:13-23.
    PubMed     Abstract available

    March 2021
  3. GRILLO E, Corsini M, Ravelli C, Zammataro L, et al
    Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
    Cancer Lett. 2021;507:80-88.
    PubMed     Abstract available

  4. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available

    February 2021
  5. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available

  6. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available

    January 2021
  7. WU PK, Hong SK, Park JI
    Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf(V600E) melanoma cells.
    Cancer Lett. 2021 Jan 10. pii: S0304-3835(21)00007.
    PubMed     Abstract available

  8. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available

  9. ZHAO Y, Li J, Ting KK, Chen J, et al
    The VE-Cadherin/beta-catenin signalling axis regulates immune cell infiltration into tumours.
    Cancer Lett. 2021;496:1-15.
    PubMed     Abstract available

    December 2020
  10. BOTELHO DE SOUZA LE, Ferreira FU, Thome CH, Brand H, et al
    Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome.
    Cancer Lett. 2020 Dec 28. pii: S0304-3835(20)30701.
    PubMed     Abstract available

    November 2020
  11. HARTMAN ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, et al
    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30635.
    PubMed     Abstract available

  12. KIM G, Bhattarai PY, Lim SC, Kim JY, et al
    PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
    Cancer Lett. 2020 Nov 27. pii: S0304-3835(20)30631.
    PubMed     Abstract available

    September 2020
  13. LIU S, Zhang J, Fang S, Su X, et al
    Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
    Cancer Lett. 2020 Sep 15. pii: S0304-3835(20)30475.
    PubMed     Abstract available

  14. SMALLEY H, Rowe JM, Nieto F, Zeledon J, et al
    Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth.
    Cancer Lett. 2020 Sep 3. pii: S0304-3835(20)30453.
    PubMed     Abstract available

    April 2020
  15. TIAN H, Kang Y, Song X, Xu Y, et al
    PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Cancer Lett. 2020;476:170-182.
    PubMed     Abstract available

  16. KUO CL, Chou HY, Chiu YC, Cheng AN, et al
    Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis.
    Cancer Lett. 2020;474:138-150.
    PubMed     Abstract available

    March 2020
  17. JEONG Y, Kim GB, Ji Y, Kwak GJ, et al
    Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade.
    Cancer Lett. 2020;472:19-28.
    PubMed     Abstract available

    February 2020
  18. LI T, Zhang C, Zhao G, Zhang X, et al
    IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
    Cancer Lett. 2020 Feb 28. pii: S0304-3835(20)30105.
    PubMed     Abstract available

    January 2020
  19. FLORES-GUZMAN F, Utikal J, Umansky V
    Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model.
    Cancer Lett. 2020 Jan 18. pii: S0304-3835(20)30024.
    PubMed     Abstract available

    September 2019
  20. VOSHTANI R, Song M, Wang H, Li X, et al
    Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment.
    Cancer Lett. 2019;465:24-35.
    PubMed     Abstract available

    May 2019
  21. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed     Abstract available

    April 2019
  22. LIANG Z, Li Y, Tian Y, Zhang H, et al
    High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Cancer Lett. 2019;447:164-173.
    PubMed     Abstract available

    March 2019
  23. CHEN Y, Sumardika IW, Tomonobu N, Winarsa Ruma IM, et al
    Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
    Cancer Lett. 2019 Mar 20. pii: S0304-3835(19)30179.
    PubMed     Abstract available

    February 2019
  24. FENG Y, Sessions EH, Zhang F, Ban F, et al
    Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084.
    PubMed     Abstract available

  25. YU M, Zhang C, Tang Z, Tang X, et al
    Intratumoral injection of gels containing losartan microspheres and (PLG-g-mPEG)-cisplatin nanoparticles improves drug penetration, retention and anti-tumor activity.
    Cancer Lett. 2019;442:396-408.
    PubMed     Abstract available

    January 2019
  26. BIANCHINI F, Portioli E, Ferlenghi F, Vacondio F, et al
    Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
    Cancer Lett. 2019 Jan 10. pii: S0304-3835(19)30012.
    PubMed     Abstract available

  27. XU X, Jin Z, Liu Y, Gong H, et al
    Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8(+) T-cell responses and reduce the immunosuppressive activity of MDSCs.
    Cancer Lett. 2019;440-441:94-105.
    PubMed     Abstract available

    November 2018
  28. BRUMMER C, Faerber S, Bruss C, Blank C, et al
    Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Cancer Lett. 2018 Nov 24. pii: S0304-3835(18)30684.
    PubMed     Abstract available

  29. TREMBLE LF, O'Brien MA, Forde PF
    Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer.
    Cancer Lett. 2018 Nov 22. pii: S0304-3835(18)30680.
    PubMed     Abstract available

  30. FURST K, Steder M, Logotheti S, Angerilli A, et al
    DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.
    Cancer Lett. 2018;442:299-309.
    PubMed     Abstract available

    October 2018
  31. CHIU CS, Tsai CH, Hsieh MS, Tsai SC, et al
    Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.
    Cancer Lett. 2018 Oct 31. pii: S0304-3835(18)30640.
    PubMed     Abstract available

    September 2018
  32. SEIP K, Jorgensen K, Haselager MV, Albrecht M, et al
    "Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment".
    Cancer Lett. 2018 Sep 18. pii: S0304-3835(18)30580.
    PubMed     Abstract available

    July 2018
  33. QIU H, Zmina PM, Huang AY, Askew D, et al
    Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
    Cancer Lett. 2018 Jul 20. pii: S0304-3835(18)30482.
    PubMed     Abstract available

  34. LEE YS, Jung YY, Park MH, Yeo IJ, et al
    Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
    Cancer Lett. 2018;433:156-164.
    PubMed     Abstract available

    May 2018
  35. MEHTA PP, Kung PP, Yamazaki S, Walls M, et al
    Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
    Cancer Lett. 2018;422:132.

  36. ZHENG Y, Wang K, Wu Y, Chen Y, et al
    Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells.
    Cancer Lett. 2018;431:31-42.
    PubMed     Abstract available

    March 2018
  37. MARSAVELA G, Aya-Bonilla CA, Warkiani ME, Gray ES, et al
    Melanoma circulating tumor cells: Benefits and challenges required for clinical application.
    Cancer Lett. 2018;424:1-8.
    PubMed     Abstract available

  38. TANG J, Zhou H, Hou X, Wang L, et al
    Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
    Cancer Lett. 2018;423:16-26.
    PubMed     Abstract available

    January 2018
  39. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30051.
    PubMed     Abstract available

  40. DI GENNARO P, Gerlini G, Caporale R, Sestini S, et al
    T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
    Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30005.
    PubMed     Abstract available

    November 2017
  41. RODRIGUEZ CI, Castro-Perez E, Longley BJ, Setaluri V, et al
    Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30749.
    PubMed     Abstract available

    September 2017
  42. AIDA S, Sonobe Y, Tanimura H, Oikawa N, et al
    MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30555.
    PubMed     Abstract available

  43. HUANG GX, Wang Y, Su J, Zhou P, et al
    Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30552.
    PubMed     Abstract available

  44. KIM SJ, Jung KH, Son MK, Park JH, et al
    Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Cancer Lett. 2017;403:339-353.
    PubMed     Abstract available

    August 2017
  45. RUZZOLINI J, Peppicelli S, Andreucci E, Bianchini F, et al
    Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30487.
    PubMed     Abstract available

  46. WANG J, Hirose H, Du G, Chong K, et al
    P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
    Cancer Lett. 2017 Aug 10. pii: S0304-3835(17)30478.
    PubMed     Abstract available

    July 2017
  47. CALERO R, Morchon E, Martinez-Argudo I, Serrano R, et al
    Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Cancer Lett. 2017 Jul 31. pii: S0304-3835(17)30457.
    PubMed     Abstract available

  48. PERES J, Maliepaard EM, Rambow F, Larue L, et al
    The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
    Cancer Lett. 2017 Jul 28. pii: S0304-3835(17)30454.
    PubMed     Abstract available

  49. CIMAS FJ, Callejas-Valera JL, Garcia-Olmo DC, Hernandez-Losa J, et al
    E1a is an exogenous in vivo tumour suppressor.
    Cancer Lett. 2017;399:74-81.
    PubMed     Abstract available

  50. BORST A, Haferkamp S, Grimm J, Rosch M, et al
    Involvement of the BH3-only pro-apoptotic BIK/NBK in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Cancer Lett. 2017 Jul 15. pii: S0304-3835(17)30431.
    PubMed     Abstract available

  51. KUZU OF, Gowda R, Sharma A, Noory MA, et al
    Improving Pharmacological Targeting of AKT in Melanoma.
    Cancer Lett. 2017 Jul 10. pii: S0304-3835(17)30419.
    PubMed     Abstract available

  52. CALAPRE L, Warburton L, Milward M, Ziman M, et al
    Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Cancer Lett. 2017 Jul 4. pii: S0304-3835(17)30412.
    PubMed     Abstract available

    June 2017
  53. KLIMKIEWICZ K, Weglarczyk K, Collet G, Paprocka M, et al
    A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects on cell interactions and cancer stem cell selection.
    Cancer Lett. 2017;396:10-20.
    PubMed     Abstract available

  54. LEE YK, Park UH, Kim EJ, Hwang JT, et al
    Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Cancer Lett. 2017 Jun 17. pii: S0304-3835(17)30396.
    PubMed     Abstract available

    April 2017
  55. WANG Y, Liu M, Jin Y, Jiang S, et al
    In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30289.
    PubMed     Abstract available

  56. LUO C, Shen J
    Research progress in advanced melanoma.
    Cancer Lett. 2017 Apr 3. pii: S0304-3835(17)30219.
    PubMed     Abstract available

  57. HOU X, Zhou H, Wang L, Tang J, et al
    Multifunctional near-infrared dye-magnetic nanoparticles for bioimaging and cancer therapy.
    Cancer Lett. 2017;390:168-175.
    PubMed     Abstract available

    February 2017
  58. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Abstract available

  59. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Abstract available

  60. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Abstract available

    January 2017
  61. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Abstract available

    October 2016
  62. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Abstract available

  63. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Abstract available

    September 2016
  64. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.